A Phase 2 interventional study of Low Dose NT-501 and High Dose NT-501 in Retinitis Pigmentosa, sponsored by Neurotech Pharmaceuticals. Completed at 11 sites in United States. Open to participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2024-08-13.
Sponsored by Neurotech Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 44 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 17th largest by enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2007, is one of 15 in phase 2, and was the 18th registered.
278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.
Browse Retinitis Pigmentosa studies →20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:
Nacuity Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Sumitomo Pharma America, Inc. · Sites in United States
Ages 18+
Octant, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 68 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 38 · Phase 3 11
First in 1993; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 27 across 179 interventional studies indexed under Retinitis Pigmentosa.
Median enrollment 21 across the 78 interventional studies, 73 across the 38 observational. Of the 69 that completed or were terminated, 30 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 119 have an industry lead sponsor. The 10 most frequent:
Neurotech Pharmaceuticals is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Neurotech Pharmaceuticals has 3 studies filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
11 of the studies in Retinitis Pigmentosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06388200Phase 3OcugenA Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | 2027-02-12 |
| NCT06912633jCyte, IncSafety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) | 2026-12 |
| NCT02086890Nova Southeastern UniversityElectro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa | 2026-12 |
| NCT04278131Bionic Sight LLCBS01 in Patients With Retinitis Pigmentosa | 2026-12-30 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
Add all 11 to your calendar (.ics) → With an account.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia. This research is being done because there are no effective therapies for people with these retinal degenerations. They are genetic disorders that affect our ability to see at night, and later cause tunnel vision and loss of central vision. Retinal degenerations affect the retina, a light sensitive layer of cells in the back of the eye. Slowly over time, these cells die and cause permanent loss of vision.
The implant is a small capsule that contains human retinal pigment epithelium cells. These cells have been given the ability to make CNTF and release it through the capsule membrane into the surrounding fluid. This study will look at the effect of the implant on vision loss by retinitis pigmentosa, Usher type II \& III, and Choroideremia. In this study, two different CNTF dose levels will be used: a high dose and a low dose in one eye, as well as a sham (or placebo) surgery in the other eye.
This study will involve about 16 visits over 1½ years for specific tests of the participant's vision and health. These visits may include visual exams, blood draw for laboratory testing, brief medical history and exam, and occasionally a questionnaire (survey), in addition to the visit for the surgical procedures. The primary effectiveness outcome for this study will be a visual acuity score one year after the implant surgery. There will be about 13 centers participating in this study, and up to 60 people enrolled across the US. Each participant joining the study who has completed initial screening will then be scheduled to have a brief surgical procedure performed on each eye, one of which will include a very small cell-filled implant. Follow-up visits for repeat assessments will be required regularly to determine if the implant being tested is safe and effective for use to treat RP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant's clinical diagnosis was consistent with retinal degeneration in the set of retinitis pigmentosa (RP) dystrophies characterized by the following features:
Exclusion Criteria:
Participant had a requirement of acyclovir and/or related products during study duration.
To be eligible for this study, the participant must have discontinued use of these products prior to enrollment and must not continue with the products until after they had completed the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NT-501 Low Dose Implant: encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina Sham Implant in Fellow Eye
Combination Product: Low Dose NT-501
NT-501 High Dose Implant: encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina Sham Implant in Fellow Eye
Combination Product: High Dose NT-501
Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery
Also known as: CNTF implant
High Dose NT-501 Implanted in study eye and fellow eye received sham surgery
Also known as: CNTF implant
The Primary Outcome is the Change in Best-corrected Visual Acuity (BCVA) Using the Electronic Visual Acuity (EVA) Technology at Month 12.
The primary efficacy endpoint was the proportion of patients demonstrating an improvement in best-corrected visual acuity (BCVA), defined as an increase of 10 letters or more at the 1-Year post-implant visit (pre-explant, if explant is completed). No response is defined as an improvement of \<10 letters.
Time frame: 12 months post-implant
Number of Participants With and Without Best Corrected Visual Acuity Response Over the 18-month Follow-up Period (Months 1, 3, 6, 12 and 18)
The key visits for efficacy assessments were Months 1, 3, 6, 12 and 18. At these time points, BCVA was measured 3 times and the mean outcome reported. The assessments were conducted by masked technicians. The change from baseline for BCVA was summarized by time. Response is defined as an improvement in visual acuity by an increase of 10 letters or more whereas no response is \<10 letters.
Time frame: From initial implant to 18 months post-implant
The total number of participant in the low dose group was 22 and the high dose group was 45 since each patient consented to treatment in one eye and sham treatment in the other eye.
| Milestone | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose Arm - Implant | High Dose Arm - Sham |
|---|---|---|---|---|
| Started | 22 | 22 | 45 | 45 |
| Completed | 22 | 22 | 41 | 41 |
| Not completed | 0 | 0 | 4 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 2 |
The primary efficacy endpoint was the proportion of patients demonstrating an improvement in best-corrected visual acuity (BCVA), defined as an increase of 10 letters or more at the 1-Year post-implant visit (pre-explant, if explant is completed). No response is defined as an improvement of \<10 letters.
| participants | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose | High Dose Arm - Sham |
|---|---|---|---|---|
| Response (Greater than or equal to 10 letter improvement) | 1 | 1 | 3 | 1 |
| No Response | 20 | 20 | 39 | 41 |
The key visits for efficacy assessments were Months 1, 3, 6, 12 and 18. At these time points, BCVA was measured 3 times and the mean outcome reported. The assessments were conducted by masked technicians. The change from baseline for BCVA was summarized by time. Response is defined as an improvement in visual acuity by an increase of 10 letters or more whereas no response is \<10 letters.
| Participants | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose | High Dose Arm - Sham |
|---|---|---|---|---|
| 1 month post-implant: Response | 1 | 1 | 3 | 1 |
| 1 month post-implant: No Response | 21 | 21 | 40 | 42 |
| 3 months post-implant: Response | 2 | 1 | 2 | 0 |
| 3 months post-implant: No Response | 20 | 21 | 40 | 42 |
| 6 months post-implant: Response | 1 | 0 | 4 | 2 |
| 6 months post-implant: No Response | 20 | 21 | 38 | 40 |
| 12 months post-implant: Response | 1 | 1 | 3 | 1 |
| 12 months post-implant: No Response | 20 | 20 | 39 | 41 |
| 18 months post-implant: Response | 0 | 2 | 2 | 0 |
| 18 months post-implant: No Response | 19 | 17 | 30 | 32 |
Collected over Adverse Events were collected from time of the consent through 18 months post-implant.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose | 0/22 (0%) | 1/22 (4.5%) | 22/22 (100%) |
| High Dose | 0/43 (0%) | 0/22 (0%) | 42/43 (97.7%) |
| Event | Low Dose | High Dose |
|---|---|---|
| Pelvic FractureInjury, poisoning and procedural complications | 1/22 | 0/22 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/22 | 0/22 |
| Event | Low Dose | High Dose |
|---|---|---|
| Conjunctival HaemorrhageEye disorders | 16/22 | 32/43 |
| Conjunctival HyperaemiaEye disorders | 11/22 | 15/43 |
| Suture related complicationInjury, poisoning and procedural complications | 10/22 | 11/43 |
| Anterior chamber cellEye disorders | 7/22 | 12/43 |
| Procedural painInjury, poisoning and procedural complications | 7/22 | 5/43 |
| NasopharyngitisInfections and infestations | 6/22 | 2/43 |
| MiosisEye disorders | 1/22 | 11/43 |
| Anterior chamber flareEye disorders | 5/22 | 10/43 |
| Foreign body sensation in eyesEye disorders | 2/22 | 10/43 |
| Eye painEye disorders | 2/22 | 7/43 |
Total number of participants in the trial was 67, with 22 participants in the Low Dose Arm and 45 participants in the High Dose Arm. Note, the participants also received a sham surgery in fellow eye on both study arms, which was used as reference therapy. No capsule was implanted in fellow eye. Baseline reports include sham as a separate column for each arm.
| Age, Continuous(Years) | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose | High Dose Arm - Sham | Total |
|---|---|---|---|---|---|
| Mean | 41.1 ± 10.5 | 41.1 ± 10.5 | 42.0 ± 11.0 | 42.0 ± 11.0 | 41.7 ± 10.8 |
| Sex: Female, Male(Participants) | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose | High Dose Arm - Sham | Total |
|---|---|---|---|---|---|
| Female | 8 | 8 | 25 | 25 | 66 |
| Male | 14 | 14 | 20 | 20 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose | High Dose Arm - Sham | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 2 | 2 | 10 |
| Not Hispanic or Latino | 19 | 19 | 43 | 43 | 124 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose | High Dose Arm - Sham | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 0 | 2 |
| Asian | 2 | 2 | 2 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 4 | 4 | 10 |
| White | 18 | 18 | 39 | 39 | 114 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Ocular History - Years Since RP Diagnosis(Years) | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose | High Dose Arm - Sham | Total |
|---|---|---|---|---|---|
| Mean | 24.66 ± 9.55 | 24.66 ± 9.55 | 21.50 ± 13.21 | 21.50 ± 13.21 | 22.52 ± 12.17 |
| Type of Ocular History(Eyes) | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose | High Dose Arm - Sham | Total |
|---|---|---|---|---|---|
| Ocular Disease | 22 | 22 | 45 | 45 | 134 |
| Ocular Surgery | 11 | 9 | 21 | 21 | 62 |
| Ocular Treatment | 2 | 2 | 2 | 2 | 8 |
| BCVA Letter Score(Letters) | Low Dose Arm - Implant | Low Dose Arm - Sham | High Dose | High Dose Arm - Sham | Total |
|---|---|---|---|---|---|
| Mean | 45.5 ± 11.2 | 44.8 ± 10.4 | 45.0 ± 10.4 | 46.7 ± 9.1 | 45.5 ± 10.3 |
Plan to share: No
Ran from Jan 2007 to primary completion in May 2009, 28 months.
Results were first posted in Aug 2024, 15 years 2 months after primary completion. A results delay was requested in Nov 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ciliary Neurotrophic Factor
Neurotech Pharmaceuticals